Concepts (50)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Biomedical Research | 3 | 2022 | 371 | 0.880 |
Why?
|
| Oxadiazoles | 1 | 2016 | 14 | 0.570 |
Why?
|
| Neoplasms | 2 | 2023 | 1033 | 0.530 |
Why?
|
| Drug Design | 1 | 2016 | 154 | 0.520 |
Why?
|
| Minority Groups | 4 | 2023 | 537 | 0.460 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 756 | 0.340 |
Why?
|
| Prostatic Neoplasms | 1 | 2016 | 794 | 0.310 |
Why?
|
| Florida | 3 | 2023 | 358 | 0.270 |
Why?
|
| Receptors, sigma | 1 | 2023 | 16 | 0.230 |
Why?
|
| Students | 3 | 2022 | 452 | 0.220 |
Why?
|
| Benzamides | 1 | 2003 | 76 | 0.220 |
Why?
|
| Pyridines | 1 | 2003 | 113 | 0.210 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2003 | 112 | 0.210 |
Why?
|
| Benzoquinones | 1 | 2021 | 34 | 0.210 |
Why?
|
| Phytotherapy | 1 | 2021 | 62 | 0.200 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2021 | 107 | 0.190 |
Why?
|
| Research Personnel | 1 | 2019 | 133 | 0.160 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2016 | 107 | 0.140 |
Why?
|
| Cell Proliferation | 2 | 2023 | 1149 | 0.130 |
Why?
|
| Structure-Activity Relationship | 1 | 2016 | 376 | 0.130 |
Why?
|
| Cell Line, Tumor | 2 | 2023 | 2128 | 0.130 |
Why?
|
| Molecular Structure | 1 | 2016 | 467 | 0.120 |
Why?
|
| Apoptosis | 2 | 2023 | 1317 | 0.120 |
Why?
|
| Humans | 7 | 2023 | 34853 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 984 | 0.110 |
Why?
|
| Cell Survival | 1 | 2016 | 818 | 0.110 |
Why?
|
| Models, Molecular | 1 | 2016 | 751 | 0.110 |
Why?
|
| Medical Oncology | 2 | 2022 | 26 | 0.100 |
Why?
|
| Program Evaluation | 2 | 2022 | 316 | 0.090 |
Why?
|
| Male | 3 | 2019 | 18870 | 0.070 |
Why?
|
| Carrageenan | 1 | 2003 | 10 | 0.060 |
Why?
|
| Spectrophotometry, Infrared | 1 | 2003 | 35 | 0.060 |
Why?
|
| Chromatography, Thin Layer | 1 | 2003 | 37 | 0.060 |
Why?
|
| Chemistry, Physical | 1 | 2003 | 44 | 0.060 |
Why?
|
| Chemical Phenomena | 1 | 2003 | 53 | 0.060 |
Why?
|
| Indomethacin | 1 | 2003 | 24 | 0.060 |
Why?
|
| Amines | 1 | 2023 | 38 | 0.060 |
Why?
|
| Indicators and Reagents | 1 | 2003 | 57 | 0.060 |
Why?
|
| Edema | 1 | 2003 | 20 | 0.060 |
Why?
|
| Chemokines | 1 | 2023 | 89 | 0.060 |
Why?
|
| Ligands | 1 | 2023 | 317 | 0.050 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2003 | 281 | 0.050 |
Why?
|
| California | 1 | 2023 | 436 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2023 | 325 | 0.050 |
Why?
|
| Career Choice | 1 | 2019 | 44 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2003 | 1534 | 0.040 |
Why?
|
| Curriculum | 1 | 2019 | 237 | 0.040 |
Why?
|
| Rats | 1 | 2003 | 3261 | 0.030 |
Why?
|
| Female | 2 | 2021 | 19873 | 0.030 |
Why?
|
| Animals | 1 | 2003 | 14307 | 0.020 |
Why?
|